Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Revenue (2016 - 2025)

Haemonetics has reported Revenue over the past 17 years, most recently at $339.0 million for Q4 2025.

  • Quarterly results put Revenue at $339.0 million for Q4 2025, down 2.75% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (down 4.02% YoY), and the annual figure for FY2025 was $1.4 billion, up 3.95%.
  • Revenue for Q4 2025 was $339.0 million at Haemonetics, up from $327.3 million in the prior quarter.
  • Over the last five years, Revenue for HAE hit a ceiling of $348.5 million in Q4 2024 and a floor of $225.0 million in Q2 2021.
  • Median Revenue over the past 5 years was $314.8 million (2023), compared with a mean of $302.2 million.
  • Biggest five-year swings in Revenue: dropped 5.65% in 2021 and later increased 24.01% in 2022.
  • Haemonetics' Revenue stood at $239.9 million in 2021, then grew by 27.26% to $305.3 million in 2022, then grew by 10.14% to $336.2 million in 2023, then grew by 3.66% to $348.5 million in 2024, then dropped by 2.75% to $339.0 million in 2025.
  • The last three reported values for Revenue were $339.0 million (Q4 2025), $327.3 million (Q3 2025), and $321.4 million (Q2 2025) per Business Quant data.